$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

$itci Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000119312518150798 Filed on May 03, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$0.00	$0.00	$95.29K
YoY Change	-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.730M	$6.380M	$6.310M
YoY Change	7.68%	1.11%	24.7%
% of Gross Profit
Research & Development	$32.44M	$30.70M	$21.54M
YoY Change	159.96%	42.55%	-8.09%
% of Gross Profit
Depreciation & Amortization	$100.0K	$82.50K	$50.43K
YoY Change	100.0%	63.59%	5.13%
% of Gross Profit
Operating Expenses	$39.17M	$37.08M	$27.85M
YoY Change	109.08%	33.16%	-2.28%
Operating Profit	-$39.17M	-$37.08M	-$27.75M
YoY Change	110.37%	33.62%	-2.61%
Interest Expense	$1.790M	$1.600M	$820.0K
YoY Change	108.14%	95.12%	24.24%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$37.37M	-$35.48M	-$26.93M
YoY Change	110.44%	31.74%	-3.27%
Income Tax	$1.600K	$0.00	$1.600K
% Of Pretax Income
Net Earnings	-$37.38M	-$35.48M	-$26.93M
YoY Change	110.44%	31.73%	-3.26%
Net Earnings / Revenue			-28265.75%
Basic Earnings Per Share
Diluted Earnings Per Share	-$683.4K	-$648.9K	-$620.6K
COMMON SHARES
Basic Shares Outstanding	54.70M shares	54.68M shares	43.41M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$403.8M	$437.0M	$367.8M
YoY Change	17.86%	18.81%	-19.36%
Cash & Equivalents	$69.77M	$74.42M	$23.60M
Short-Term Investments	$334.0M	$362.6M	$344.2M
Other Short-Term Assets	$5.900M	$6.100M	$3.800M
YoY Change	-3.28%	60.53%	-44.12%
Inventory
Prepaid Expenses	$2.400M
Receivables			$68.20K
Other Receivables			$0.00
Total Short-Term Assets	$409.7M	$443.2M	$371.6M
YoY Change	17.44%	19.25%	-19.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.275M	$1.350M	$605.7K
YoY Change	102.8%	122.85%	-17.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$78.83K	$77.29K	$75.77K
YoY Change	4.05%	2.02%	5.41%
Total Long-Term Assets	$2.413M	$2.485M	$681.4K
YoY Change	242.38%	264.74%	-15.17%
TOTAL ASSETS
Total Short-Term Assets	$409.7M	$443.2M	$371.6M
Total Long-Term Assets	$2.413M	$2.485M	$681.4K
Total Assets	$412.1M	$445.6M	$372.3M
YoY Change	17.89%	19.7%	-19.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.379M	$10.04M	$7.158M
YoY Change	202.99%	40.25%	265.33%
Accrued Expenses	$13.60M	$9.600M	$9.200M
YoY Change	161.54%	4.35%	31.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.94M	$19.65M	$16.32M
YoY Change	171.95%	20.43%	82.4%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.800M	$2.800M	$2.900M
YoY Change	-3.45%	-3.45%	45.0%
Total Long-Term Liabilities	$2.800M	$2.800M	$2.947M
YoY Change	-3.82%	-4.97%	49.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.94M	$19.65M	$16.32M
Total Long-Term Liabilities	$2.800M	$2.800M	$2.947M
Total Liabilities	$21.69M	$22.45M	$19.27M
YoY Change	119.63%	16.53%	76.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$480.1M	-$442.7M	-$336.4M
YoY Change	35.56%	31.6%	52.3%
Common Stock	$871.5M	$867.2M	$689.7M
YoY Change	25.55%	25.72%	2.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$390.4M	$423.2M	$353.0M
YoY Change
Total Liabilities & Shareholders Equity	$412.1M	$445.6M	$372.3M
YoY Change	17.89%	19.7%	-19.71%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$37.38M	-$35.48M	-$26.93M
YoY Change	110.44%	31.73%	-3.26%
Depreciation, Depletion And Amortization	$100.0K	$82.50K	$50.43K
YoY Change	100.0%	63.59%	5.13%
Cash From Operating Activities	-$33.62M	-$26.98M	-$16.40M
YoY Change	35.07%	64.54%	-16.54%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	$295.1K	$28.50K
YoY Change	-71.43%	935.48%	635.62%
Acquisitions
YoY Change
Other Investing Activities	$28.98M	$63.57M	-$8.840M
YoY Change	-6.37%	-819.12%	-192.37%
Cash From Investing Activities	$28.95M	$63.28M	-$8.870M
YoY Change	-6.22%	-813.39%	-192.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	337.8K	220.0K
YoY Change	-100.0%	53.54%	37.5%
NET CHANGE
Cash From Operating Activities	-33.62M	-26.98M	-16.40M
Cash From Investing Activities	28.95M	63.28M	-8.870M
Cash From Financing Activities	0.000	337.8K	220.0K
Net Change In Cash	-4.670M	36.63M	-25.05M
YoY Change	-177.96%	-246.23%	152.52%
FREE CASH FLOW
Cash From Operating Activities	-$33.62M	-$26.98M	-$16.40M
Capital Expenditures	-$20.00K	$295.1K	$28.50K
Free Cash Flow	-$33.60M	-$27.28M	-$16.43M
YoY Change	35.37%	66.05%	-16.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54696380	shares
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23598325
CY2017Q4	itci	Securities Remaining Authorized Amount For Issuance SecuritiesRemainingAuthorizedAmountForIssuance	178000000
CY2018Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2257963
CY2018Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7355955
CY2018Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	428364000
CY2018Q1	us-gaap	Assets Current AssetsCurrent	443153579
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2773890
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	867152094
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10038850
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1239750
CY2018Q1	us-gaap	Assets Assets	445639072
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	312400000
CY2018Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	362584126
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1240000
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	32700000
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	1240000
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	363824000
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	279700000
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74421386
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54694718	shares
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54694718	shares
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	5469
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2797349
CY2018Q1	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	1058435
CY2018Q1	us-gaap	Liabilities Liabilities	22450117
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	445639072
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19652768
CY2018Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	33300000
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	77293
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6148067
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1349765
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4123655
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-442728858
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	18.29
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4379957	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2842927	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.21
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4379957	shares
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	42000
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	427340000
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.29
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	423188955
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48642225
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1611846
CY2017Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6424221
CY2017Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	452722000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	469215328
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2692788
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	862479505
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6173539
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-799224
CY2017Q4	us-gaap	Assets Assets	471486699
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	426540921
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	799000
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	37300000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37790114
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54597679	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54597679	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	5460
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2840132
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	1058435
CY2017Q4	us-gaap	Liabilities Liabilities	17049738
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	471486699
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14209606
CY2017Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	26200000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	75765
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4884293
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1137171
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3829959
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-407248780
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3755736	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.75
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	454436961
CY2017	us-gaap	Depreciation Depreciation	50429
CY2017	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y0M0D
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-141965
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25043900
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26908051
CY2017Q1	us-gaap	Depreciation Depreciation	50429
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6310486
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26931982
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-26139
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2367851
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3403099
CY2017Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	93323
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-243811
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	822175
CY2017Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	47726
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8869524
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16398561
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	27849444
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	224185
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-26933582
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27754157
CY2017Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	25531
CY2017Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	101944891
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28498
CY2017Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	93103865
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	224185
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21538958
CY2017Q1	us-gaap	Revenues Revenues	95287
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4160678
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y0M0D
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.904	pure
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43385605	shares
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	56298
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	1200000
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	48000
CY2018Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> </div>
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	36631272
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35920604
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	us-gaap	Depreciation Depreciation	82498
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	Intra-Cellular Therapies, Inc.
CY2018Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001567514
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6381228
CY2018Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35480078
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1519726
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3865311
CY2018Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	15342
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1265302
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1604148
CY2018Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	47699
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	63277475
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26983999
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	37084226
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	337796
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-35480078
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-37084226
CY2018Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-440526
CY2018Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	91870300
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	295092
CY2018Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	155442867
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	337796
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30702998
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4287103
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y0M0D
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2818	shares
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	13.77
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.023	pure
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M19D
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.47
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.858	pure
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	18.76
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	651569	shares
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	24530	shares
CY2018Q1	dei	Trading Symbol TradingSymbol	ITCI
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54676175	shares
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> </div>
CY2018Q1	itci	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2	P9Y9M18D
CY2018Q1	itci	Cash And Cash Equivalent Maximum Maturity Period CashAndCashEquivalentMaximumMaturityPeriod	P3M
CY2018Q1	itci	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm	P5Y9M18D
CY2018Q1	itci	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm	P9Y2M12D
CY2018Q1	itci	Available For Sale Securities Maturity Period AvailableForSaleSecuritiesMaturityPeriod	More than three months
CY2018Q1	itci	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit	1100000
CY2018Q1	itci	Annual Effective Tax Rate AnnualEffectiveTaxRate	0.00	pure

Files In Submission

Name	View Source	Status
0001193125-18-150798-index-headers.html	Edgar Link	pending
0001193125-18-150798-index.html	Edgar Link	pending
0001193125-18-150798.txt	Edgar Link	pending
0001193125-18-150798-xbrl.zip	Edgar Link	pending
d557887d10q.htm	Edgar Link	pending
d557887dex311.htm	Edgar Link	pending
d557887dex312.htm	Edgar Link	pending
d557887dex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
itci-20180331.xml	Edgar Link	completed
itci-20180331.xsd	Edgar Link	pending
itci-20180331_cal.xml	Edgar Link	unprocessable
itci-20180331_def.xml	Edgar Link	unprocessable
itci-20180331_lab.xml	Edgar Link	unprocessable
itci-20180331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

2018 Q2 Form 10-Q Financial Statement

#000119312518150798 Filed on May 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI Intra-Cellular Therapies, Inc. Stock $itci

2018 Q2 Form 10-Q Financial Statement

#000119312518150798 Filed on May 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci